316 related articles for article (PubMed ID: 33007075)
21. Effects of Total Body Irradiation on Hematopoietic Cell Transplantation Outcomes in Pediatric Acute Myeloid Leukemia with Prior Central Nervous System Involvement.
Takahashi T; Lake AJ; Wachter F; Calderon FA; Dandoy C; Keating AK
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38763417
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
23. Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
Orvain C; Ali N; Othus M; Rodríguez-Arbolí E; Milano F; Le CM; Sandmaier BM; Scott BL; Appelbaum FR; Walter RB
Am J Hematol; 2024 May; 99(5):862-870. PubMed ID: 38380817
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
Alam N; Atenafu EG; Kuruvilla J; Uhm J; Lipton JH; Messner HA; Kim DH; Seftel M; Gupta V
Bone Marrow Transplant; 2015 Sep; 50(9):1180-6. PubMed ID: 26121109
[TBL] [Abstract][Full Text] [Related]
25. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
26. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
27. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Jain T; Tsai HL; Elmariah H; Vachhani P; Karantanos T; Wall SA; Gondek LP; Bashey A; Keyzner A; Tamari R; Grunwald MR; Abedin S; Nadiminti KV; Iqbal M; Gerds AT; Viswabandya A; McCurdy SR; Al Malki MM; Varadhan R; Ali H; Gupta V; Jones RJ; Otoukesh S
Haematologica; 2023 Dec; 108(12):3321-3332. PubMed ID: 37408464
[TBL] [Abstract][Full Text] [Related]
28. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
29. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.
Schmaelter AK; Labopin M; Socié G; Itälä-Remes M; Blaise D; Yakoub-Agha I; Forcade E; Cornelissen J; Ganser A; Beelen D; Labussière-Wallet H; Passweg J; Savani BN; Schmid C; Nagler A; Mohty M
Blood Cancer J; 2020 Mar; 10(3):26. PubMed ID: 32127519
[TBL] [Abstract][Full Text] [Related]
30. Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
Michelis FV; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Lipton JH; Loach D; Seftel MD; Uhm J; Alam N; Lambie A; McGillis L; Messner HA
Bone Marrow Transplant; 2015 Jul; 50(7):907-13. PubMed ID: 25822226
[TBL] [Abstract][Full Text] [Related]
31. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
[TBL] [Abstract][Full Text] [Related]
32. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
33. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H; Kato M; Kudo K; Taga T; Tomizawa D; Miyamura T; Goto H; Inagaki J; Koh K; Terui K; Ogawa A; Kawano Y; Inoue M; Sawada A; Kato K; Atsuta Y; Yamashita T; Adachi S
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
[TBL] [Abstract][Full Text] [Related]
35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
36. Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Nagler A; Labopin M; Dholaria B; Ciceri F; Fraccaroli A; Blaise D; Fanin R; Bruno B; Forcade E; Vydra J; Chevallier P; Bulabois CE; Jindra P; Bornhäuser M; Canaani J; Sanz J; Savani BN; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M
Transplant Cell Ther; 2022 Nov; 28(11):773.e1-773.e8. PubMed ID: 36031079
[TBL] [Abstract][Full Text] [Related]
37. Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.
Lee CJ; Labopin M; Beelen D; Finke J; Blaise D; Ganser A; Itälä-Remes M; Chevallier P; Labussière-Wallet H; Maertens J; Yakoub-Agha I; Bourhis JH; Mailhol A; Mohty M; Savani BN; Nagler A
Am J Hematol; 2019 Apr; 94(4):431-438. PubMed ID: 30597620
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
[TBL] [Abstract][Full Text] [Related]
39. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.
Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ
Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
